EMEA-002944-PIP01-20
Key facts
| Active substance |
2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid tris(hydroxymethyl)aminomethane salt (1:1) (PF-06882961)
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0452/2021
|
| PIP number |
EMEA-002944-PIP01-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pfizer Europe MA EEIG
E-mail: pip_enquiries@pfizer.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|